Advances in Immunology最新文献_第10页

Antibody dependent enhancement: Unavoidable problems in vaccine development. 抗体依赖性增强:疫苗开发中不可避免的问题。

3区医学

Advances in Immunology Pub Date : 2021-01-01 DOI: 10.1016/bs.ai.2021.08.003

Lele Xu, Zhiqian Ma, Yang Li, Zhaoxia Pang, Shuqi Xiao

引用次数: 27

The transcription factors GFI1 and GFI1B as modulators of the innate and acquired immune response. 转录因子GFI1和GFI1B作为先天和获得性免疫反应的调节剂。

3区医学

Advances in Immunology Pub Date : 2021-01-01 Epub Date: 2021-04-23 DOI: 10.1016/bs.ai.2021.03.003

Jennifer Fraszczak, Tarik Möröy

{"title":"The transcription factors GFI1 and GFI1B as modulators of the innate and acquired immune response.","authors":"Jennifer Fraszczak, Tarik Möröy","doi":"10.1016/bs.ai.2021.03.003","DOIUrl":"https://doi.org/10.1016/bs.ai.2021.03.003","url":null,"abstract":"GFI1 and GFI1B are small nuclear proteins of 45 and 37kDa, respectively, that have a simple two-domain structure: The first consists of a group of six c-terminal C2H2 zinc finger motifs that are almost identical in sequence and bind to very similar, specific DNA sites. The second is an N-terminal 20 amino acid SNAG domain that can bind to the pocket of the histone demethylase KDM1A (LSD1) near its active site. When bound to DNA, both proteins act as bridging factors that bring LSD1 and associated proteins into the vicinity of methylated substrates, in particular histone H3 or TP53. GFI1 can also bring methyl transferases such as PRMT1 together with its substrates that include the DNA repair proteins MRE11 and 53BP1, thereby enabling their methylation and activation. While GFI1B is expressed almost exclusively in the erythroid and megakaryocytic lineage, GFI1 has clear biological roles in the development and differentiation of lymphoid and myeloid immune cells. GFI1 is required for lymphoid/myeloid and monocyte/granulocyte lineage decision as well as the correct nuclear interpretation of a number of important immune-signaling pathways that are initiated by NOTCH1, interleukins such as IL2, IL4, IL5 or IL7, by the pre TCR or -BCR receptors during early lymphoid differentiation or by T and B cell receptors during activation of lymphoid cells. Myeloid cells also depend on GFI1 at both stages of early differentiation as well as later stages in the process of activation of macrophages through Toll-like receptors in response to pathogen-associated molecular patterns. The knowledge gathered on these factors over the last decades puts GFI1 and GFI1B at the center of many biological processes that are critical for both the innate and acquired immune system.","PeriodicalId":50862,"journal":{"name":"Advances in Immunology","volume":"149 ","pages":"35-94"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.ai.2021.03.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38986921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Series Page 系列页面

3区医学

Advances in Immunology Pub Date : 2021-01-01 DOI: 10.1016/s0065-2776(21)00008-0

引用次数: 0

Thymoproteasome optimizes positive selection of CD8⁺ T cells without contribution of negative selection. 胸腺蛋白酶体优化了CD8+ T细胞的正向选择，而没有负向选择的贡献。

3区医学

Advances in Immunology Pub Date : 2021-01-01 Epub Date: 2021-05-01 DOI: 10.1016/bs.ai.2021.03.001

Izumi Ohigashi, Yousuke Takahama

引用次数: 0

Follicular lymphoma dynamics. 滤泡性淋巴瘤动力学。

3区医学

Advances in Immunology Pub Date : 2021-01-01 Epub Date: 2021-06-18 DOI: 10.1016/bs.ai.2021.05.002

Pierre Milpied, Anita K Gandhi, Guillaume Cartron, Laura Pasqualucci, Karin Tarte, Bertrand Nadel, Sandrine Roulland

{"title":"Follicular lymphoma dynamics.","authors":"Pierre Milpied, Anita K Gandhi, Guillaume Cartron, Laura Pasqualucci, Karin Tarte, Bertrand Nadel, Sandrine Roulland","doi":"10.1016/bs.ai.2021.05.002","DOIUrl":"10.1016/bs.ai.2021.05.002","url":null,"abstract":"Follicular lymphoma (FL) is an indolent yet challenging disease. Despite a generally favorable response to immunochemotherapy regimens, a fraction of patients does not respond or relapses early with unfavorable prognosis. For the vast majority of those who initially respond, relapses will repeatedly occur with increasing refractoriness to available treatments. Addressing the clinical challenges in FL warrants deep understanding of the nature of treatment-resistant FL cells seeding relapses, and of the biological basis of early disease progression. Great progress has been made in the last decade in the description and interrogation of the (epi)genomic landscape of FL cells, of their major dependency to the tumor microenvironment (TME), and of the stepwise lymphomagenesis process, from healthy to subclinical disease and to overt FL. A new picture is emerging, in which an ever-evolving tumor-TME duo sparks a complex and multilayered clonal and functional heterogeneity, blurring the discovery of prognostic biomarkers, patient stratification and reliable designs of risk-adapted treatments. Novel technological approaches allowing to decipher both tumor and TME heterogeneity at the single-cell level are beginning to unravel unsuspected cell dynamics and plasticity of FL cells. The upcoming drawing of a comprehensive functional picture of FL within its ecosystem holds great promise to address the unmet medical needs of this complex lymphoma.","PeriodicalId":50862,"journal":{"name":"Advances in Immunology","volume":" ","pages":"43-103"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.ai.2021.05.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39112291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Copyright 版权

3区医学

Advances in Immunology Pub Date : 2021-01-01 DOI: 10.1016/s0065-2776(21)00010-9

引用次数: 0

Series Page 系列页面

3区医学

Advances in Immunology Pub Date : 2021-01-01 DOI: 10.1016/s0065-2776(21)00046-8

引用次数: 0

Series Page 系列页面

3区医学

Advances in Immunology Pub Date : 2021-01-01 DOI: 10.1016/s0065-2776(21)00020-1

引用次数: 0

Copyright 版权

3区医学

Advances in Immunology Pub Date : 2021-01-01 DOI: 10.1016/s0065-2776(21)00048-1

引用次数: 0

Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics. 肾脏疾病与补体的作用：将补体与免疫效应途径和疗法联系起来。

3区医学

Advances in Immunology Pub Date : 2021-01-01 Epub Date: 2021-11-19 DOI: 10.1016/bs.ai.2021.09.001

Tilo Freiwald, Behdad Afzali

{"title":"Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.","authors":"Tilo Freiwald, Behdad Afzali","doi":"10.1016/bs.ai.2021.09.001","DOIUrl":"10.1016/bs.ai.2021.09.001","url":null,"abstract":"The complement system is an ancient and phylogenetically conserved key danger sensing system that is critical for host defense against pathogens. Activation of the complement system is a vital component of innate immunity required for the detection and removal of pathogens. It is also a central orchestrator of adaptive immune responses and a constituent of normal tissue homeostasis. Once complement activation occurs, this system deposits indiscriminately on any cell surface in the vicinity and has the potential to cause unwanted and excessive tissue injury. Deposition of complement components is recognized as a hallmark of a variety of kidney diseases, where it is indeed associated with damage to the self. The provenance and the pathophysiological role(s) played by complement in each kidney disease is not fully understood. However, in recent years there has been a renaissance in the study of complement, with greater appreciation of its intracellular roles as a cell-intrinsic system and its interplay with immune effector pathways. This has been paired with a profusion of novel therapeutic agents antagonizing complement components, including approved inhibitors against complement components (C)1, C3, C5 and C5aR1. A number of clinical trials have investigated the use of these more targeted approaches for the management of kidney diseases. In this review we present and summarize the evidence for the roles of complement in kidney diseases and discuss the available clinical evidence for complement inhibition.","PeriodicalId":50862,"journal":{"name":"Advances in Immunology","volume":"152 ","pages":"1-81"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905641/pdf/nihms-1785441.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39789672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0